Neurocrine Biosciences | NBIX - Trade Debtors



Neurocrine Biosciences reported $481.1M in Trade Debtors for its fiscal quarter ending in September of 2024.

Trade Debtors Change Date
AbbVie USD 11.72B 225M Jun/2024
Acadia Pharmaceuticals USD 110.36M 30K Sep/2024
Agios Pharmaceuticals USD 3.12M 644K Sep/2024
ALKERMES USD 370.18M 273K Sep/2024
Alnylam Pharmaceuticals USD 353.85M 44.37M Sep/2024
Amgen USD 7.32B 383M Sep/2024
Biogen USD 1.99B 90.1M Sep/2024
BioMarin Pharmaceutical USD 777.55M 86.32M Sep/2024
Cytokinetics USD 0 834K Jun/2024
Dynavax Technologies USD 75.28M 12.65M Sep/2024
Exelixis USD 269.71M 126.88M Sep/2024
Gilead Sciences USD 4.59B 76M Sep/2024
Halozyme Therapeutics USD 558.8M 344.28M Sep/2024
Incyte USD 758.45M 19.4M Sep/2024
Intra Cellular Therapies USD 145.61M 104K Sep/2024
Ionis Pharmaceuticals USD 18M 9M Sep/2024
Neurocrine Biosciences USD 481.1M 12.9M Sep/2024
Pfizer USD 15.09B 135M Jun/2024
Prothena USD 0 0 Jun/2024
Regeneron Pharmaceuticals USD 12.21B 6.5B Sep/2024
Repligen USD 129.03M 5.79M Sep/2024
Sarepta Therapeutics USD 449.58M 57.32M Sep/2024
Teva Pharmaceutical Industries USD 3.77B 310M Jun/2024
Ultragenyx Pharmaceutical USD 93.3M 14.98M Sep/2024
Vertex Pharmaceuticals USD 1.75B 94.5M Sep/2024